Table V.

microRNAs found to significantly differentiate serous tumors from endometnoid tumors.

microRNA	Fold changea	p-value	EA/BEb	SA/BEb	mRNA targetf
miR-218	5.9	0.001	−6.7d	−1.4	ZEB2
miR-9	−9.8	0.011	9.3c	−1.1	NEDD4
miR-423-5p	−4.6	0.011	1.7	−2.7c
miR-542-3p	5.8	0.018	−2.5	2.3	BLCAP, PARP12, FIGF
miR-490-3p	11.6	0.024	1.8	20.4
miR-504	8.1	0.026	−131.6e	−16.3d	GPC4, OLFML2A
miR-338-3p	10.9	0.030	−1.9	5.9
miR-9*	−13.6	0.030	−15.4c	−2.3
miR-146a	−8.9	0.031	43.1c	4.9	ERBB4, ABL2
miR-130a	5.9	0.032	−3.2d	1.8	IGF1, ZAK
let-7c	3.2	0.033	−7.7c	−2.4
miR-375	−232.7	0.035	333.9c	1.4	PDK1
miR-675	80.2	0.037	−1.5	53.2	RB1
miR-570	27.6	0.041	−1.1	26.0	ABL2, XYLT1, IGF1R
miR-99a/100	4.8	0.041	−7.5	−1.6	PPP3CA, IGF1R
miR-518e	19.8	0.048	1.4	27.3c
miR-450a	5.4	0.050	−2.1	2.6

^aFold change is presented as serous tumors compared to endometrioid tumors.

^bFold changes for endometrioid adenocarcinoma (EA) compared to benign endometrium (BE) and for serous adenocarcinoma (SA) compared to benign endometrium (BE) for the same miRNAs.

^cp<0.05,

^dp<0.01,

^ep<0.001

^fExperimentally validated targets are shown in bold. TargetScan predicted targets were filtered in the same manner as those presented in Table IV.